Myung-Ju Ahn 1 , Sang-We Kim 2 , Byoung-Chul Cho 3 , Jin Seok Ahn 1 , Dae Ho Lee 2 , Jong-Mu Sun 4 , Dan Massey 5 , Miyoung Kim 6 , Yang Shi 7 , Keunchil Park 8 Show Affiliations »
Abstract
BACKGROUND: This phase II single-arm trial evaluated afatinib, an irreversible inhibitor of the ErbB receptor family as third-line treatment of Korean patients with advanced non-small cell lung cancer (NSCLC) and tumors with wild-type EGFR. Currently, no standard therapy exists for these patients. METHODS: Eligible patients had stage IIIB/IV wild-type EGFR lung adenocarcinoma and had failed to benefit from two previous lines of chemotherapy but had not received anti-EGFR treatment. Patients received oral afatinib at 40 mg per day until disease progression or occurrence of intolerable adverse events (AEs). The primary endpoint was confirmed objective tumor response (OR) rate (confirmed complete response [CR] or partial response [PR]). Secondary endpoints included disease control rate (DCR; OR or stable disease for ≥6 weeks), progression-free survival (PFS), and safety. RESULTS: Forty-two patients received afatinib treatment, and 38 of those were included in efficacy analyses. No confirmed CRs or PRs were reported. DCR was 24% (9 of 38 patients), with a median disease control duration of 19.3 weeks. Median PFS was 4.1 weeks (95% confidence interval: 3.9-8.0). Frequently reported AEs (mainly grades 1 and 2) were rash/acne (88%), diarrhea (62%), and stomatitis (57%). CONCLUSION: Heavily pretreated patients with wild-type EGFR NSCLC treated with afatinib monotherapy did not experience an objective response and only 24% had disease stabilization lasting more than 6 weeks. AEs were manageable and consistent with the expected safety profile. ©AlphaMed Press; the data published online to support this summary is the property of the authors.
BACKGROUND: This phase II single-arm trial evaluated afatinib , an irreversible inhibitor of the ErbB receptor family as third-line treatment of Korean patients with advanced non-small cell lung cancer (NSCLC ) and tumors with wild-type EGFR . Currently, no standard therapy exists for these patients . METHODS: Eligible patients had stage IIIB/IV wild-type EGFR lung adenocarcinoma and had failed to benefit from two previous lines of chemotherapy but had not received anti-EGFR treatment. Patients received oral afatinib at 40 mg per day until disease progression or occurrence of intolerable adverse events (AEs ). The primary endpoint was confirmed objective tumor response (OR) rate (confirmed complete response [CR] or partial response [PR]). Secondary endpoints included disease control rate (DCR ; OR or stable disease for ≥6 weeks), progression-free survival (PFS), and safety. RESULTS: Forty-two patients received afatinib treatment, and 38 of those were included in efficacy analyses. No confirmed CRs or PRs were reported. DCR was 24% (9 of 38 patients ), with a median disease control duration of 19.3 weeks. Median PFS was 4.1 weeks (95% confidence interval: 3.9-8.0). Frequently reported AEs (mainly grades 1 and 2) were rash /acne (88%), diarrhea (62%), and stomatitis (57%). CONCLUSION: Heavily pretreated patients with wild-type EGFR NSCLC treated with afatinib monotherapy did not experience an objective response and only 24% had disease stabilization lasting more than 6 weeks. AEs were manageable and consistent with the expected safety profile. ©AlphaMed Press; the data published online to support this summary is the property of the authors.
Entities: Chemical
Disease
Gene
Species
Mesh： See more »
Substances： See more »
Year: 2014
PMID： 24868099 PMCID： PMC4077442 DOI： 10.1634/theoncologist.2013-0419
Source DB: PubMed Journal: Oncologist ISSN： 1083-7159